398.00 +3.54 (0.90%)
Pre-Market: 9:05AM EDT
|Bid||398.00 x 800|
|Ask||399.99 x 800|
|Day's Range||389.10 - 403.03|
|52 Week Range||134.80 - 403.45|
|PE Ratio (TTM)||197.92|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||302.11|
American Century Ultra Fund (TWCUX) got it right with Wabtec — also known as Westinghouse Air Brake. The $11.4 billion portfolio is underweight in industrials, but its managers nonetheless made room for the locomotive equipment maker, starting in 2010. "Wabtec fits our quality, durable-growth philosophy based on the management team, their track record and a business with a strong operating margin averaging 17% over the last five years," client portfolio manager Kevin Lewis told IBD.
All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.
On Wednesday, May 23, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. This Thursday morning, WallStEquities.com looks at the performance of these four Medical Appliances & Equipment stocks: Abbott Laboratories (NYSE: ABT), ABIOMED Inc. (NASDAQ: ABMD), Align Technology Inc. (NASDAQ: ALGN), and Amedica Corp. (NASDAQ: AMDA).
Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively. The company’s pre-tax margin grew from 10.7% in 2013 to 20.5% in 2017. ABMD beat the medical device industry and the S&P 500 between 2013 and 2017. The market cap gained 680% between 2013 and 2017.
Varian Medical (VAR) opts to spread radiotherapy accessibility in Latin America through Brazil MOH, other international ventures of the company hold promise.
A rapidly changing healthcare environment in the United States, sluggish first quarter, declining margins and foreign exchange headwinds continue to hurt DENTSPLY SIRONA (XRAY).
ABIOMED (ABMD) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
Successive product launches and a marked progress in precision medicine initiatives boost Thermo Fisher's (TMO) performance.
Veeva (VEEV) strengthens its position by providing the life sciences industry with a streamlined commercial database besides notable technological innovations.
Veeva Systems' (VEEV) new commercial data warehouse establishes a solid data foundation, which will boost AI and analytics in the MedTech industry.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.